Drugs

Piotr Wysocki: CAR-T cells targeting CD70 for renal cell cancer – promising results of a phase I COBALT-RCC study (AACR2024)

Photo taken from Piotr Wysocki/LinkedIn

Apr 10, 2024, 08:41

Piotr Wysocki: CAR-T cells targeting CD70 for renal cell cancer – promising results of a phase I COBALT-RCC study (AACR2024)

Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn:

“CD70 is a member of the tumor necrosis factor superfamily 7 (TNFSF7). It is highly expressed in renal cell cancer (RCC), especially in clear-cell and sarcomatoid histology, making it a promising immunogenic target. Sumanta K. Pal has presented results of a phase I, multicenter, first-in-human clinical trial (COBALT-RCC) evaluating the activity of immunotherapy based on CD70-targeting allogenic CAR-T cells in 16 patients with relapsed/refractory clear-cell renal cell cancer (ccRCC). All patients were previously treated with immunotherapy and anti-VEGF agents.

All patients (median age 63) had undergone lymphodepletion (cytarabine and cyclophosphamide) and received CAR-T cells (1-3 infusions).

Cytokine release syndrome (CRS of grade 1-2) was observed in 8 (50%) patients, and there were no grade ≥3 CRS events (Table 2). Four (25%) patients experienced serious adverse events (CRS). The median time to CRS onset was 1 day, with a median duration of 2 days. No patients experienced immune effector cell–associated neurotoxicity syndrome (ICANS) or Graft vs Host Disease.

The CAR-T cell treatment resulted in disease control in 13 (81%) patients, including 12 patients with disease stabilization and 1 patient (6%) with complete response. The patient experiencing CR remains disease-free at 3 years.

The results of COBALT-RCC study provide promising data demonstrating that CAR-T cell-based therapy can be active in patients with solid cancer and may lead to long-term complete response in some patients with ccRCC.”

Piotr Wysocki: CAR-T cells targeting CD70 for renal cell cancer – promising results of a phase I COBALT-RCC study (AACR2024)

Additional information.
Source: Piotr Wysocki/LinkedIn

anti-VEGF cancer CAR-T cells CD70 clear-cell renal cell cancer (ccRCC) clinical trial COBALT-RCC COBALT-RCC study Cyclophosphamide cytarabine Cytokine release syndrome disease control Graft vs Host Disease immune effector cell–associated neurotoxicity syndrome immunotherapy Jagiellonian University Hospital lymphodepletion neurotoxicity syndrome OncoDaily Oncology patients Piotr Wysocki renal cell cancer Sumanta K. Pal TNFSF7 tumor necrosis factor

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage